ATE529100T1 - Vektorsystem enthaltend nanopartikeln gleichmässiger grösse,welche aus zumindestens einem polymer und einem positiv geladenen polysaccharid bestehen,und herstellungsverfahren dieses systems - Google Patents

Vektorsystem enthaltend nanopartikeln gleichmässiger grösse,welche aus zumindestens einem polymer und einem positiv geladenen polysaccharid bestehen,und herstellungsverfahren dieses systems

Info

Publication number
ATE529100T1
ATE529100T1 AT03760766T AT03760766T ATE529100T1 AT E529100 T1 ATE529100 T1 AT E529100T1 AT 03760766 T AT03760766 T AT 03760766T AT 03760766 T AT03760766 T AT 03760766T AT E529100 T1 ATE529100 T1 AT E529100T1
Authority
AT
Austria
Prior art keywords
polymer
positively charged
production method
uniform size
charged polysaccharide
Prior art date
Application number
AT03760766T
Other languages
English (en)
Inventor
Malam Aboubakar
Andrei Maksimenko
Christine Chaumont
Valerie Polard
Original Assignee
Bioalliance Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioalliance Pharma filed Critical Bioalliance Pharma
Application granted granted Critical
Publication of ATE529100T1 publication Critical patent/ATE529100T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5138—Organic macromolecular compounds; Dendrimers obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5161—Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5192—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/906—Drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Optics & Photonics (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Nanotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Processes Of Treating Macromolecular Substances (AREA)
  • Luminescent Compositions (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
AT03760766T 2002-06-20 2003-06-20 Vektorsystem enthaltend nanopartikeln gleichmässiger grösse,welche aus zumindestens einem polymer und einem positiv geladenen polysaccharid bestehen,und herstellungsverfahren dieses systems ATE529100T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0207668A FR2841137B1 (fr) 2002-06-20 2002-06-20 Systeme de vectorisation comprenant des nanoparticules de taille homogene d'au moins un polymere et d'au moins un polysaccharide charge positivement
PCT/FR2003/001909 WO2004000287A1 (fr) 2002-06-20 2003-06-20 Systeme de vectorisation comprenant des nanoparticules de taille homogene d'au moins un polymere et d'au moins un polysaccharide charge positivement et son procede de preparation

Publications (1)

Publication Number Publication Date
ATE529100T1 true ATE529100T1 (de) 2011-11-15

Family

ID=29719922

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03760766T ATE529100T1 (de) 2002-06-20 2003-06-20 Vektorsystem enthaltend nanopartikeln gleichmässiger grösse,welche aus zumindestens einem polymer und einem positiv geladenen polysaccharid bestehen,und herstellungsverfahren dieses systems

Country Status (10)

Country Link
US (1) US8062669B2 (de)
EP (1) EP1513506B1 (de)
JP (1) JP2005533078A (de)
AT (1) ATE529100T1 (de)
AU (1) AU2003263249B2 (de)
CA (1) CA2488942A1 (de)
ES (1) ES2375628T3 (de)
FR (1) FR2841137B1 (de)
IL (1) IL165830A (de)
WO (1) WO2004000287A1 (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1661559A1 (de) * 2004-11-25 2006-05-31 NanoDel Technologies GmbH Verabreichungssystem hergestellt durch ein Miniemulsionsverfahren
ATE419842T1 (de) * 2004-09-14 2009-01-15 Nanodel Technologies Gmbh Abgabevehikel mit nanoteilchen
WO2006038552A1 (ja) * 2004-10-01 2006-04-13 Eisai R & D Management Co., Ltd. 微粒子含有組成物およびその製造方法
WO2006056362A2 (en) * 2004-11-25 2006-06-01 Nanodel Technologies Gmbh Delivery vehicle manufactured by the miniemulsion method
ES2277743B2 (es) * 2005-06-02 2008-12-16 Universidade De Santiago De Compostela Nanoparticulas que comprenden quitosano y ciclodextrina.
JP5536334B2 (ja) * 2005-10-14 2014-07-02 マリーナ バイオテック，インコーポレイテッド Ｒｎａ治療用ペプチドリボ核酸縮合体粒子のための化合物及び方法
WO2008048272A2 (en) * 2006-10-21 2008-04-24 University Of South Florida Method of drug delivery by carbon nanotube-chitosan nanocomplexes
US8536324B2 (en) * 2005-10-21 2013-09-17 University Of South Florida Method of drug delivery by carbon nanotube-chitosan nanocomplexes
CA2628313A1 (en) * 2005-11-04 2007-05-31 Bio Syntech Canada Inc. Composition and method for efficient delivery of nucleic acids to cells using chitosan
US20110142890A1 (en) * 2006-05-24 2011-06-16 Advanced In Vitro Cell Technologies, S.A. Nanoparticles of chitosan and hyaluronan for the administration of active molecules
EP1859792A1 (de) * 2006-05-24 2007-11-28 Advanced in Vitro Cell Technologies, S.L. Nanopartikel aus Chitosan und Hyaluronan für die Verabreichung von Wirkstoffen
CN100460018C (zh) * 2006-07-26 2009-02-11 郑州大学 复溶性聚氰基丙烯酸酯纳米粒,其制备方法及制药用途
JP2010503640A (ja) * 2006-09-15 2010-02-04 エフエムシー バイオポリマー エイエス オリゴヌクレオチド非ウイルスデリバリーシステム
KR100882611B1 (ko) * 2006-11-14 2009-02-12 주식회사 키토라이프 표적 리간드로서 폴릭산이 도입된 유전자 전달체용저분자량 수용성 키토산 나노입자 및 이의 제조방법
EP2152757A1 (de) * 2007-05-02 2010-02-17 Agency for Science, Technology and Research Funktionalisierung von nanopartikeln durch glucosaminderivate
US8703204B2 (en) 2007-05-03 2014-04-22 Bend Research, Inc. Nanoparticles comprising a cholesteryl ester transfer protein inhibitor and anon-ionizable polymer
US8309129B2 (en) * 2007-05-03 2012-11-13 Bend Research, Inc. Nanoparticles comprising a drug, ethylcellulose, and a bile salt
WO2008149230A2 (en) 2007-06-04 2008-12-11 Pfizer Products Inc. Nanoparticles comprising drug, a non-ionizable cellulosic polymer and tocopheryl polyethylene glycol succinate
EP2162120B1 (de) 2007-06-04 2016-05-04 Bend Research, Inc Nanopartikel mit nicht ionisierbarem zellulosepolymer und amphipilem nicht ionisierbarem blockcopolymer
EP2231169B1 (de) 2007-12-06 2016-05-04 Bend Research, Inc. Pharmazeutische zusammensetzungen mit nanopartikeln und resuspensionsmaterial
WO2009073216A1 (en) 2007-12-06 2009-06-11 Bend Research, Inc. Nanoparticles comprising a non-ionizable polymer and an amine-functionalized methacrylate copolymer
EP2153821A1 (de) * 2008-08-06 2010-02-17 BioAlliance Pharma Orale Formulierungen von Camptothecin-Derivaten
CN101780105B (zh) * 2009-01-20 2011-09-28 沈阳兴齐制药有限公司 小牛血去蛋白提取物的滴眼液
ITTO20130317A1 (it) * 2013-04-19 2014-10-20 Idea Medical Devices S R L Dispositivo medico comprendente una struttura di supporto a base di chitosano
CN108956488B (zh) * 2018-04-23 2020-11-10 山东省医疗器械产品质量检验中心 一种壳聚糖或壳聚糖盐中蛋白质含量的测定方法
CN112295013B (zh) * 2020-10-30 2022-06-21 北京福爱乐科技发展有限公司 一种消炎型快速止血医用胶材料及其制备方法
CN112220962B (zh) * 2020-10-30 2022-06-21 北京福爱乐科技发展有限公司 一种快速止血的医用胶材料及其制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3632754A (en) * 1968-02-12 1972-01-04 Lescarden Ltd Use of chitin for promoting wound healing
FR2504408B1 (fr) * 1981-04-24 1986-02-14 Couvreur Patrick Procede de preparation de particules submicroscopiques, particules ainsi obtenues et compositions pharmaceutiques les contenant
US4474769A (en) * 1983-05-13 1984-10-02 Pfanstiehl Laboratories, Inc. Chitosan as a contraceptive
FR2649321A1 (fr) * 1989-07-07 1991-01-11 Inst Nat Sante Rech Med Compositions a base de derives nucleotidiques, leurs procedes de preparation, et leurs utilisations notamment en tant que compositions pharmaceutiques
FR2724935B1 (fr) * 1994-09-27 1996-12-20 Centre Nat Rech Scient Compositions nanoparticulaires contenant des derives nucleotidiques, leur preparation et leur emploi en therapeutique
DE59610423D1 (de) * 1995-02-10 2003-06-12 Christian Noe Partikulare arzneiform
US5830883A (en) * 1995-11-06 1998-11-03 Duquesne University Of The Holy Ghost Methods of creating a unique chitosan and employing the same to form complexes with drugs, delivery of the same within a patient and a related dosage form
FR2775435B1 (fr) * 1998-02-27 2000-05-26 Bioalliance Pharma Nanoparticules comprenant au moins un polymere et au moins un compose apte a complexer un ou plusieurs principes actifs

Also Published As

Publication number Publication date
US8062669B2 (en) 2011-11-22
FR2841137A1 (fr) 2003-12-26
EP1513506A1 (de) 2005-03-16
WO2004000287A1 (fr) 2003-12-31
US20060134220A1 (en) 2006-06-22
CA2488942A1 (fr) 2003-12-31
AU2003263249B2 (en) 2009-09-10
EP1513506B1 (de) 2011-10-19
IL165830A (en) 2008-11-26
AU2003263249A1 (en) 2004-01-06
ES2375628T3 (es) 2012-03-02
IL165830A0 (en) 2006-01-15
JP2005533078A (ja) 2005-11-04
FR2841137B1 (fr) 2004-08-13

Similar Documents

Publication Publication Date Title
ATE529100T1 (de) Vektorsystem enthaltend nanopartikeln gleichmässiger grösse,welche aus zumindestens einem polymer und einem positiv geladenen polysaccharid bestehen,und herstellungsverfahren dieses systems
Bhat et al. Polysaccharide-based nanomedicines targeting lung cancer
SE9504495L (sv) Linjär blockpolymer innefattande urea- och uretangrupper, förfarande för framställning av linjära blockpolymerer samt användning av blockpolymererna som implantat
Molinaro et al. Biocompatibility of thermosensitive chitosan-based hydrogels: an in vivo experimental approach to injectable biomaterials
Ahmad et al. Chitosan centered bionanocomposites for medical specialty and curative applications: a review
DE60316579D1 (de) System zur abgabe von wirkstoffen mit einem hydrophoben cellulose-derivat
Carpa et al. Double-network chitosan-based hydrogels with improved mechanical, conductive, antimicrobial, and antibiofouling properties
Li et al. Chitosan‐carrageenan polyelectrolyte complex for the delivery of protein drugs
WO2007086882A3 (en) Biological polymer with differently charged portions
WO2004047768A3 (en) Buoyant polymer particles delivering therapeutic agents
AU2002350592A1 (en) Ph-sensitive polymer
BRPI0413396A (pt) dispersão aquosa, método para produzir uma dispersão aquosa, camada de pelìcula e artigo
PT1137670E (pt) Processo de ligacao transversal de polissacaridos carboxilados
TW200727912A (en) Amphiphilic block copolymers and nano particles comprising the same
ATE344021T1 (de) Verfahren und zusammensetzungen zur verbesserung der bioadhäsiven eigenschaften von polymeren
BRPI0410956A (pt) pelìculas com base em óxido de polietileno e sistemas de liberação de droga feitos delas
NZ302658A (en) Cellulose particles that also have cationic groups on the inside, their method of preparation and use
Karakurt et al. Effect of saccharides coating on antibacterial potential and drug loading and releasing capability of plasma treated polylactic acid films
NZ596876A (en) Dermal delivery compositions comprising active agent-calcium phosphate particle complexes and methods of using the same
EP0719783A3 (de) Phosphorylierte Saccharide und Verfahren zu deren Herstellung
EP1399501A4 (de) Negativ geladenes amphiphiles blockcopolymer als arzneistoffträger und komplex davon mit postitiv geladenem arzneistoff
ATE427983T1 (de) Bariumsulfat, verfahren zu dessen herstellung und dessen verwendung
ATE457326T1 (de) Polymer
DE60108325D1 (de) Pharmazeutische oder diätetische zusammensetzungen aus pilzen und deren verwendung
AU2001233714A1 (en) Use of an acetylated pre-gelled starch with a high content of amylose

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties